Excessive daytime sleepiness (EDS) is a cardinal feature of obstructive sleep apnea (OSA). It confers significant disability, including compromised safety when driving or at work, impairments in work/academic performance and personal/family relationships, as well as increased prevalence of psychiatric and medical comorbidities. Treatment planning in patients with OSA-related EDS is highly specialized, considering the psychiatric and medical comorbidities that can complicate treatment decisions. Successfully treating persistent OSA-related EDS has been shown to improve medical comorbidities such as hypertension and diabetes. However, developing personalized treatment strategies to optimally manage complex patients often poses significant challenges to clinicians.
Join Drs. Richard Bogan and Paula Schweitzer as they discuss case 2 of this 3-part CMEO BriefCase series and provide guidance on the nuances of personalizing treatment selection and strategies to monitor treatment effectiveness to provide safe, effective, long-term care.
At the end of this CME/CE activity, participants should be able to position treatment strategies for OSA-related EDS based on individual patients’ profiles.
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in sleep, pulmonology, psychiatry, neurology and/or primary care.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Bogan reports the following financial relationships: Consultant: Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. Grants: Axsome Therapeutics, Inc.; Eisai Inc.; Flamel Technologies; Fresca Medical, Inc.; Harmony Biosciences, LLC; Idorsia Pharmaceuticals; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Philips; Suven Life Sciences; and Takeda Pharmaceuticals U.S.A., Inc. Speakers Bureau: Eisai Inc.; Harmony Biosciences, LLC; and Jazz Pharmaceuticals, Inc.
Dr. Schweitzer reports the following financial relationships: Advisory Board: Jazz Pharmaceuticals, Inc. Consultant: Apinmed, Inc. and Jazz Pharmaceuticals, Inc. Research Support: Apnimed, Inc; Avadel; Inspire Medical Systems; Jazz Pharmaceuticals, Inc.; and Suven Life Sciences
Marlon (Tony) Graham, MD (peer reviewer)
Kashemi D. Rorie, PhD (planning committee)
Evan Luberger (planning committee)
Susan H. Yarbrough, CHCP (planning committee)
Sharon Tordoff (planning committee)
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at (877) CME-PROS or (877) 263-7767
NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-22-062-H01-P.